In this third episode, Michael addresses the concept of quality of life and how one’s choice of treatment impacts the future. He profiles his own challenges with post-operative side effects including urinary incontinence, bowel issues, erectile dysfunction and the emotional turmoil associated with treatments. He addresses the surgical pathology report and how the results are interpreted in terms of cancer’s spread and if indicated, further treatment. He concludes this segment addressing challenges in depression and his return to a normal life.
In this second episode, Michael presents the basics of decision making as it pertains to critical choices he faced, including selecting the type of prostate biopsy. He explains what is communicated in a biopsy pathology report. In addition, Michael introduces us to a radical prostatectomy using a robotic-assisted procedure, along with the reported advantages of high-volume surgeons. He concludes this segment addressing bone scans, and their use in uncovering the spread of prostate cancer.
In this first episode, Michael introduces us to his personal journey with prostate cancer. It begins with addressing PSA and the role of this tumor marker in risk assessment for prostate cancer. He discusses active surveillance as a treatment option, family history, symptoms (and in his case, a lack of symptoms), and the need to expand one’s health care team to include a urologist. He concludes this segment with introducing the MRI fusion-guided biopsy.
Mark the 2022 Prostate Cancer Awareness Month with Dr. Michael Lutz, president of the MIU Men’s Health Foundation, and prostate cancer survivor and former Navy pilot, Craig Reiner, as they discuss the current state of diagnosis and treatment as well as the many changes that have taken place in understanding this disease since Prostate Cancer Awareness month was first established in 1999 and designated as National Prostate Cancer Awareness Month in 2003. Go here for “Flying High.” This podcast is brought to you in part by BlueEarth Diagnostics.